Elevance Health, Inc. $ELV Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. reduced its position in Elevance Health, Inc. (NYSE:ELV) by 60.4% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 2,036 shares of the company’s stock after selling 3,106 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Elevance Health were worth $778,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. GLOBALT Investments LLC GA grew its stake in shares of Elevance Health by 0.4% during the 1st quarter. GLOBALT Investments LLC GA now owns 6,306 shares of the company’s stock worth $2,743,000 after purchasing an additional 24 shares during the period. Elser Financial Planning Inc increased its holdings in shares of Elevance Health by 3.0% in the 1st quarter. Elser Financial Planning Inc now owns 882 shares of the company’s stock valued at $384,000 after purchasing an additional 26 shares in the last quarter. Checchi Capital Advisers LLC increased its holdings in shares of Elevance Health by 1.0% in the 1st quarter. Checchi Capital Advisers LLC now owns 2,737 shares of the company’s stock valued at $1,190,000 after purchasing an additional 27 shares in the last quarter. Hemington Wealth Management increased its holdings in shares of Elevance Health by 13.3% in the 1st quarter. Hemington Wealth Management now owns 230 shares of the company’s stock valued at $100,000 after purchasing an additional 27 shares in the last quarter. Finally, Aspen Investment Management Inc increased its holdings in shares of Elevance Health by 2.6% in the 1st quarter. Aspen Investment Management Inc now owns 1,048 shares of the company’s stock valued at $456,000 after purchasing an additional 27 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Susan D. Devore purchased 1,200 shares of the firm’s stock in a transaction on Tuesday, August 19th. The shares were bought at an average cost of $312.15 per share, with a total value of $374,580.00. Following the purchase, the director directly owned 3,502 shares of the company’s stock, valued at approximately $1,093,149.30. This trade represents a 52.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ELV has been the subject of a number of research analyst reports. Mizuho increased their price target on shares of Elevance Health from $342.00 to $420.00 and gave the company an “outperform” rating in a report on Thursday, October 9th. Guggenheim increased their price target on shares of Elevance Health from $360.00 to $398.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. JPMorgan Chase & Co. cut their price target on shares of Elevance Health from $472.00 to $384.00 and set an “overweight” rating for the company in a report on Tuesday, July 22nd. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Friday, July 18th. Finally, Morgan Stanley increased their price objective on shares of Elevance Health from $316.00 to $359.00 and gave the company an “equal weight” rating in a research note on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $404.72.

Elevance Health Price Performance

Shares of NYSE ELV opened at $348.93 on Friday. The stock has a market cap of $78.57 billion, a price-to-earnings ratio of 14.85, a PEG ratio of 1.27 and a beta of 0.59. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The company’s 50-day moving average price is $321.94 and its 200 day moving average price is $355.81. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Thursday, July 17th. The company reported $8.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.30 by ($0.46). Elevance Health had a return on equity of 17.59% and a net margin of 2.83%.The firm had revenue of $49.42 billion for the quarter, compared to analyst estimates of $48.26 billion. During the same period in the prior year, the business earned $10.12 earnings per share. Elevance Health’s revenue for the quarter was up 14.3% on a year-over-year basis. As a group, research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.